The international surgical journal with global reach

Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382: 1599-1607

Published: 15th June 2020

Authors: Agnelli G, Becattini C, Meyer G, Munoz A, Huisman MV, Connors JM et al.

Conclusion

Some 1155 patients with a DVT and cancer were randomly assigned apixaban or dalteparin low molecular weight heparin injections for six months. Respective rates of recurrent venous thromboembolism were similar: 5.6 versus 7.9 per cent, P<0.001 for non-inferiority. Bleeding complication rates were also similar.

Pubmed Link